MRUS - IBI Research On Merus: Elucidating The Prospects Of An Antibody Innovator
I remember my sense of shock some half-dozen years ago when I read a recommendation to sell shares of a company. The recommendation was not based on any long-term fundamentals. Rather, it was that over the next six months the funds could be employed more profitably elsewhere. - Phillip Fisher (The Father of Growth Investing)
As a lucrative endeavor, bioscience investing has extremely high market volatility. A negative market sentiment can cause significant market decline across the life science sector. If you're unfamiliar with the intrinsic behavior of this sector, you can suffer great losses.